We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » New Label Recommends Lower Starting Dose for BMS Cancer Drug
New Label Recommends Lower Starting Dose for BMS Cancer Drug
November 16, 2007
The FDA has approved new labeling for Bristol-Myers Squibb’s (BMS) leukemia drug Sprycel (dasatinib) that recommends a lower starting dose of 100 mg once daily.